Calibre Post Acute: No Correction Plan Filed - NM
The violation at Calibre Post Acute involved a resident with dementia, insomnia and major depressive disorder who had been taking the same 20-milligram dose of escitalopram since arriving at the facility in October 2024.
Federal inspectors found that when the facility's consultant pharmacist recommended evaluating a dose reduction in July 2025, the attending physician simply wrote "disagree with the pharmacist recommendation" and "resident with good response, maintain current dose."
The doctor provided no clinical rationale explaining why the reduction should not be attempted.
Federal regulations require physicians to document their reasoning when declining pharmacist recommendations for gradual dose reductions. The rule exists because unnecessary medications can cause dangerous drug interactions and adverse side effects in elderly patients.
The resident had been prescribed multiple psychiatric medications simultaneously. Along with the 20-milligram escitalopram dose for depression, he received oxcarbazepine for depression and trazodone for insomnia.
His oxcarbazepine order revealed concerning prescribing patterns. Initially ordered as an anticonvulsant in October 2024, it was discontinued in May 2025, then immediately reordered the same day for depression instead.
The facility's Director of Nursing confirmed during an October interview that the resident had remained on identical doses of escitalopram and oxcarbazepine since his admission nearly a year earlier. She acknowledged the pharmacist had recommended the dose reduction and that the provider had declined without documentation.
When asked about the missing justification, the facility's Medical Director told inspectors that gradual dose reductions for antidepressants should be attempted if residents showed no signs of depression. He confirmed that providers were expected to document clinical rationales when refusing such recommendations.
The inspection found no evidence anywhere in the resident's medical record of the required clinical reasoning for maintaining the current antidepressant dose.
Escitalopram belongs to a class of antidepressants called selective serotonin reuptake inhibitors. At 20 milligrams daily, the resident was receiving the maximum recommended dose for most adults. Standard medical practice calls for using the lowest effective dose, particularly in elderly patients who face higher risks of medication side effects.
The pharmacist's recommendation came nearly nine months after the resident began the medication, providing ample time to assess its effectiveness and determine whether a lower dose might work equally well.
Federal guidelines emphasize that nursing home residents should receive gradual dose reductions for psychoactive medications unless clinically contraindicated. The process, known as a GDR, helps identify patients who no longer need their current doses or who might benefit from lower amounts.
The facility's failure to document reasoning for refusing the pharmacist's recommendation violated federal standards designed to protect residents from unnecessary medication exposure. Without proper justification, inspectors could not determine whether keeping the resident on the maximum antidepressant dose served his medical interests.
The violation affected multiple residents beyond this case. Inspectors reviewed three residents for depression-related medication management and found documentation problems in one-third of the cases examined.
This represented a systemic breakdown in the facility's medication review process. Consultant pharmacists conduct monthly reviews specifically to identify opportunities for safer, more appropriate prescribing. When physicians dismiss their recommendations without explanation, the safety net fails.
The resident continued receiving the same medication regimen at the time of inspection, nearly three months after the pharmacist's unanswered recommendation. His medical record contained no subsequent attempts to evaluate dose reduction or document why the current regimen remained medically necessary.
Federal inspectors classified the violation as having potential for minimal harm but affecting some residents. The finding suggests broader problems with medication management oversight at the 88-bed facility on Sagecrest Avenue.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Calibre Post Acute, LLC from 2025-11-18 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: June 20, 2026 · Our methodology
Calibre Post Acute, LLC in Las Cruces, NM was cited for violations during a health inspection on November 18, 2025.
Federal regulations require physicians to document their reasoning when declining pharmacist recommendations for gradual dose reductions.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.